Business
PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance
NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical
About this update from Pavmed Inc.
[{"type":"text","content":"NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) of compliance with Nasdaq Listing Rule 5550(a)(2) after 10 consecutive days with a closing bid price of at least $1 per share.\n “We are pleased to have regained full compliance with Nasdaq’s continued listing requirements,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “The New Year is off to a great start. Additionally, we recently participated in a successful PortIO™ FDA pre-submission meeting and are already seeing a surge of interest in our EsoGuard™ LDT Esophageal DNA Test following its commercial launch last month. We look forward to updating investors as we continue to execute on the significant upcoming milestones outlined in our most recent business update.” About PAVmed PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to advance innovative products to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its five lead technologies provide groundbreaking approaches to carpal tunnel syndrome (CarpX™), precancerous conditions of the esophagus (EsoGuard™/EsoCheck™), vascular access (PortIO™), pediatric ear infections (DisappEAR™) and medical infusions (NextFlo™). The company is also developing innovative products in other areas, such as catheters and tissue ablation, while seeking to further expand its pipeline through engagements with clinician innovators and leading academic medical centers. For more information, please visit www.pavmed.com, follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on LinkedIn. Forwa...